Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
Purpose
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out if low-dose cisplatin given weekly together with radiation therapy is the same or better than high-dose cisplatin given every 3 weeks together with radiation therapy in treating patients with head and neck cancer.
Conditions
- Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Hypopharyngeal Squamous Cell Carcinoma
- Advanced Laryngeal Squamous Cell Carcinoma
- Advanced Oropharyngeal Squamous Cell Carcinoma
- Squamous Cell Carcinoma of Unknown Primary
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Pathologically (histologically or cytologically) proven diagnosis of SCCHN of the oropharynx, larynx, hypopharynx, or p16-positive unknown primary prior to registration; specimen from cervical lymph nodes with a well-defined primary site documented clinically or radiologically is acceptable; in patients with carcinoma of unknown primary this will be sufficient for pathologic confirmation without a clinically or radiographically defined primary site - For patients with oropharyngeal cancer (OPC)/cancer of unknown primary (CUP): P16 status based on local site immunohistochemical tissue staining is required. A cell block obtained from a fine needle aspiration (FNA) biopsy specimen may be used as the sole diagnostic tissue. Centers are encouraged to contact the pathology chair for clarification - Note: Institutions must screen patients for p16 status by immunohistochemistry (IHC) in order to be eligible for the trial using a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. A rigorous laboratory accreditation process similar to the United States (U.S.) CLIA certification, such as the provincial accreditation status offered by the Ontario Laboratory Accreditation (OLA) Program in Canada, the College of American Pathologists (CAP), or an equivalent accreditation in other countries, is acceptable. - The p16 results must be reported on the pathology report being submitted. The p16 positivity is defined as > 70% of tumor cells showing strong nuclear and/or cytoplasmic immunostaining with p16 antibody. - For patients with laryngeal and hypopharyngeal primaries: Analysis of p16 status is NOT required - Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations. Simple tonsillectomy or local excision of the primary without removal of nodal disease is permitted, as is excision removing gross nodal disease but with intact primary site. Limited neck dissections retrieving =< 4 nodes are permitted and considered as non-therapeutic nodal excisions - Clinical stage (American Joint Committee on Cancer [AJCC], 8th ed.), including no distant metastases based on the following diagnostic workup: - History/physical examination within 60 days prior to registration - One of the following imaging studies is required within 60 days prior to registration: - Computed tomography (CT) scan of neck (diagnostic quality with contrast, unless contraindicated) OR - Magnetic resonance imaging (MRI) of the neck (diagnostic quality with contrast, unless contraindicated) OR - Fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT of the neck; the CT component must be of diagnostic quality with contrast, unless contraindicated. - Note: A diagnostic quality CT or MRI with contrast or FDG-PET/CT scan of neck performed for the purposes of radiation planning may serve as both staging and planning tools - One of the following imaging studies is required within 60 days prior to registration: - FDG-PET/CT of the chest; FDG-PET/CT scan is strongly preferred and highly recommended to be used for eligibility OR - Chest CT - Exam with laryngopharyngoscopy (mirror or in office direct procedure acceptable) within 70 days prior to registration; - Eligibility by patient cohort; - Non-OPC/p16-negative OPC Cohort; Tumor Site: Larynx/Hypopharynx; Clinical Staging (AJCC, 8th ed.): T3-4 N0 or T1-4 N1-3 T2 N0 (hypopharynx only) - Tumor Site: p16-negative OPC; Clinical Staging (AJCC, 8th ed.): T2N1, T1-4 N2-3, or T3-4 N0-1 - p16-positive OPC/CUP Cohort; - Tumor Site: OPC; Smoking Status: =< 10 pack-years; Clinical Staging (AJCC, 8th ed.): T1-3 N2-3 or T4 N0-3 - Tumor Site: OPC; Smoking Status: > 10 pack-years; Clinical Staging (AJCC, 8th ed.): T1N2-3, T2N1-3 or T3-4 N0-3 - Tumor Site: CUP; Smoking Status: Any; Clinical Staging (AJCC, 8th ed.): T0 N2-3 Note: Cigar and pipe tobacco consumption is not included in calculating the lifetime pack-years. Marijuana consumption is likewise not considered in this calculation. There is also no clear scientific evidence regarding the role of chewing tobacco-containing products in oropharyngeal cancer, although this is possibly more concerning given the proximity of the oral cavity and oropharynx. In any case, investigators should not count use of non-cigarette tobacco products in the pack-years calculation. - Age >= 18 - Zubrod (Eastern Cooperative Oncology Group [ECOG]) performance status of 0-1 within 14 days prior to registration - Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (within 30 days prior to registration) - Platelets >= 75,000 cells/mm^3 (within 30 days prior to registration) - Hemoglobin >= 8.0 g/dL (within 30 days prior to registration) - Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dL is acceptable) - Calculated creatinine clearance (CrCl) >= 50 mL/min by the Cockcroft-Gault formula (within 30 days prior to registration) - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 30 days prior to registration) (not applicable to patients with known Gilbert's syndrome) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x institutional ULN (within 30 days prior to registration) - Known human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and CD4 T Cell count > 200 cells/mm^3 are eligible for this trial. Testing is not required for entry into protocol - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes - Willing to use highly effective contraceptives for participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) during therapy and for 14 months (females); for 11 months (males) following last dose of cisplatin; this inclusion is necessary because the treatment in this study may be significantly teratogenic - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria
- Patients with oral cavity cancer, nasopharynx cancer, or p16-negative cancer of unknown primary (CUP) - Recurrence of the study cancer - Definitive clinical or radiologic evidence of distant metastatic disease - Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, any prior exposure to cisplatin is excluded - Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields - Severe, active co-morbidity defined as follows: - Unstable angina requiring hospitalization in the last 6 months - Myocardial infarction within the last 6 months - New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.) - Persistent grade 3-4 (CTCAE version 5.0) electrolyte abnormalities that cannot be reversed despite replacement as indicated by repeat testing - Patient must not have an active infection requiring IV antibiotics prior to registration; - Other chronic renal disease like nephrotic syndrome, that could be worsened by cisplatin therapy - History of allogenic organ transplantation - Any symptomatic peripheral sensory neuropathy grade >= 2 (CTCAE version 5.0); - Pregnancy and individuals unwilling to discontinue nursing - History of hypersensitivity to cisplatin or platinum-containing compounds
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental ARM I (high-dose cisplatin, radiation therapy) |
NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity. |
|
Experimental Arm II (low-dose cisplatin, radiation therapy) |
NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity. |
|
Experimental Arm III (high-dose cisplatin, radiation therapy) |
p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity. |
|
Experimental Arm IV (low-dose cisplatin, radiation therapy) |
p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Mobile, Alabama 36607
Site Public Contact
251-435-3942
Jonesboro, Arkansas 72401
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Anaheim, California 92806
Antioch, California 94531
Auburn, California 95602
Auburn, California 95603
Berkeley, California 94704
Beverly Hills, California 90211
Carmichael, California 95608
Carmichael, California 95608
Dublin, California 94568
Site Public Contact
877-642-4691
Elk Grove, California 95758
Fremont, California 94538
Fresno, California 93720
Fresno, California 93720
La Jolla, California 92093
Los Angeles, California 90027
Los Angeles, California 90048
Site Public Contact
310-423-8965
Marysville, California 95901
Site Public Contact
530-749-4400
Modesto, California 95355
Modesto, California 95356
Mountain View, California 94040
Oakland, California 94611
Oakland, California 94611
Ontario, California 91761
Palo Alto, California 94301
Palo Alto, California 94304
Rancho Cordova, California 95670
Redwood City, California 94063
Site Public Contact
877-642-4691
Richmond, California 94801
Rocklin, California 95765
Rohnert Park, California 94928
Roseville, California 95661
Roseville, California 95661
Roseville, California 95661
Roseville, California 95678
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95816
Sacramento, California 95817
Site Public Contact
916-734-3089
Sacramento, California 95823
Sacramento, California 95823
San Francisco, California 94115
San Francisco, California 94115
Site Public Contact
877-827-3222
San Francisco, California 94158
San Jose, California 95119
San Jose, California 95124
San Leandro, California 94577
San Rafael, California 94903
Santa Clara, California 95051
Santa Rosa, California 95403
South San Francisco, California 94080
South San Francisco, California 94080
Stockton, California 95210
Sunnyvale, California 94086
Truckee, California 96161
Site Public Contact
530-582-6450
Vacaville, California 95688
Vallejo, California 94589
Walnut Creek, California 94596
Woodland, California 95695
Denver, Colorado 80205
Denver, Colorado 80218
Golden, Colorado 80401
Lafayette, Colorado 80026
Lone Tree, Colorado 80124
Washington, District of Columbia 20037
Site Public Contact
202-741-2981
Aventura, Florida 33180
Site Public Contact
954-461-2180
Bay Pines, Florida 33744
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
305-243-2647
Plantation, Florida 33324
Site Public Contact
305-243-2647
Tampa, Florida 33607
Tampa, Florida 33612
Tampa, Florida 33612
Augusta, Georgia 30912
Aurora, Illinois 60504
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60612
Site Public Contact
312-864-5204
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Hines, Illinois 60141
Site Public Contact
708-202-8387
Kewanee, Illinois 61443
Macomb, Illinois 61455
Mattoon, Illinois 61938
Maywood, Illinois 60153
Site Public Contact
708-226-4357
O'Fallon, Illinois 62269
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61636
Peru, Illinois 61354
Princeton, Illinois 61356
Rockford, Illinois 61114
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Urbana, Illinois 61801
Washington, Illinois 61571
Ankeny, Iowa 50023
Site Public Contact
515-282-2921
Clive, Iowa 50325
Site Public Contact
515-241-3305
Clive, Iowa 50325
Creston, Iowa 50801
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Des Moines, Iowa 50316
Site Public Contact
515-241-8704
West Des Moines, Iowa 50266-7700
Site Public Contact
515-343-1000
West Des Moines, Iowa 50266
Kansas City, Kansas 66160
Olathe, Kansas 66061
Overland Park, Kansas 66210
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Lexington, Kentucky 40504
Lexington, Kentucky 40504
Lexington, Kentucky 40509
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
New Orleans, Louisiana 70112
New Orleans, Louisiana 70112
Bath, Maine 04530
Biddeford, Maine 04005
Brewer, Maine 04412
Site Public Contact
800-987-3005
Portland, Maine 04102
Site Public Contact
207-885-7565
Sanford, Maine 04073
Site Public Contact
207-459-1600
Sanford, Maine 04073
Scarborough, Maine 04074
South Portland, Maine 04106
Baltimore, Maryland 21201
Baltimore, Maryland 21201
Site Public Contact
800-888-8823
Bel Air, Maryland 21014
Site Public Contact
443-643-3010
Columbia, Maryland 21044
Site Public Contact
443-546-1300
Glen Burnie, Maryland 21061
Site Public Contact
410-553-8100
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Brighton, Michigan 48114
Brighton, Michigan 48114
Brighton, Michigan 48116
Site Public Contact
800-865-1125
Brownstown, Michigan 48183
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clinton Township, Michigan 48038
Dearborn, Michigan 48126
Detroit, Michigan 48202
Detroit, Michigan 48236
Flint, Michigan 48503
Flint, Michigan 48503
Livonia, Michigan 48154
Novi, Michigan 48374
Novi, Michigan 48377
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Southfield, Michigan 48075
Warren, Michigan 48093
West Bloomfield, Michigan 48322
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Columbus, Mississippi 39705
Grenada, Mississippi 38901
Gulfport, Mississippi 39502
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Cape Girardeau, Missouri 63703
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Jefferson City, Missouri 65109
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
North Kansas City, Missouri 64116
Rolla, Missouri 65401
Rolla, Missouri 65401
Site Public Contact
573-458-6379
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Butte, Montana 59701
Site Public Contact
406-723-2621
Lebanon, New Hampshire 03756
Albuquerque, New Mexico 87102
Buffalo, New York 14263
Glens Falls, New York 12801
Site Public Contact
518-926-6700
Rochester, New York 14620
Site Public Contact
585-341-8113
Rochester, New York 14642
Site Public Contact
585-275-5830
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Pinehurst, North Carolina 28374
Supply, North Carolina 28462
Site Public Contact
910-754-4716
Wilkesboro, North Carolina 28659
Site Public Contact
888-716-9253
Wilmington, North Carolina 28401
Site Public Contact
910-251-1839
Wilmington, North Carolina 28401
Site Public Contact
910-342-3000
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Bismarck, North Dakota 58501
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Akron, Ohio 44304
Avon, Ohio 44011
Site Public Contact
800-641-2422
Barberton, Ohio 44203
Centerville, Ohio 45459
Centerville, Ohio 45459
Cleveland, Ohio 44106
Cleveland, Ohio 44109
Cleveland, Ohio 44111
Cleveland, Ohio 44195
Columbus, Ohio 43210
Dayton, Ohio 45409
Site Public Contact
937-276-8320
Dayton, Ohio 45409
Dayton, Ohio 45415
Dayton, Ohio 45415
Franklin, Ohio 45005-1066
Franklin, Ohio 45005
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Mansfield, Ohio 44906
Mayfield Heights, Ohio 44124
Medina, Ohio 44256
Mentor, Ohio 44060
Ravenna, Ohio 44266
Sandusky, Ohio 44870
Strongsville, Ohio 44136
Sylvania, Ohio 43560
Toledo, Ohio 43606
Troy, Ohio 45373
Wooster, Ohio 44691
Oklahoma City, Oklahoma 73104
Bryn Mawr, Pennsylvania 19010
Erie, Pennsylvania 16544
Site Public Contact
814-452-5000
Hershey, Pennsylvania 17033-0850
Jefferson Hills, Pennsylvania 15025
Media, Pennsylvania 19063
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
Paoli, Pennsylvania 19301
Philadelphia, Pennsylvania 19111
Site Public Contact
215-728-4790
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Wexford, Pennsylvania 15090
Wynnewood, Pennsylvania 19096
Charleston, South Carolina 29425
Greenwood, South Carolina 29646
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Collierville, Tennessee 38017
Memphis, Tennessee 38120
Houston, Texas 77030
Houston, Texas 77030
Site Public Contact
800-553-2278
Salt Lake City, Utah 84112
Saint Johnsbury, Vermont 05819
Alexandria, Virginia 22304
Fairfax, Virginia 22031
Fairfax, Virginia 22033
Bellevue, Washington 98004
Site Public Contact
425-454-2148
Kirkland, Washington 98034
Site Public Contact
425-899-6000
Seattle, Washington 98109
Site Public Contact
800-804-8824
Seattle, Washington 98109
Site Public Contact
800-804-8824
Seattle, Washington 98133
Site Public Contact
206-606-5800
Seattle, Washington 98195
Site Public Contact
800-804-8824
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Antigo, Wisconsin 54409
Eau Claire, Wisconsin 54701
Johnson Creek, Wisconsin 53038
La Crosse, Wisconsin 54601
Madison, Wisconsin 53705
Site Public Contact
608-256-1901
Madison, Wisconsin 53792
Site Public Contact
800-622-8922
Marshfield, Wisconsin 54449
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53295
Site Public Contact
888-469-6614
Minocqua, Wisconsin 54548
Mukwonago, Wisconsin 53149
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Rhinelander, Wisconsin 54501
Rice Lake, Wisconsin 54868
Stevens Point, Wisconsin 54481
Stevens Point, Wisconsin 54482
Waukesha, Wisconsin 53188
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
Weston, Wisconsin 54476
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT05050162
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVES: I. To determine whether radiation with low-dose cisplatin weekly is superior in terms of acute toxicity, as measured by the T-scores (TAME method), to radiation with high-dose cisplatin every 3 weeks for patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). (Phase II) II. To determine whether radiation with low-dose cisplatin weekly is non-inferior to radiation with high-dose cisplatin every 3 weeks in terms of overall survival (OS) for patients with locoregionally advanced SCCHN. (Phase III) III. To determine whether radiation with low-dose cisplatin weekly is superior in terms of acute toxicity, as measured by the T-scores (TAME method), to radiation with high-dose cisplatin every 3 weeks for patients with locoregionally advanced SCCHN. (Phase III) SECONDARY OBJECTIVES: I. To assess and compare progression-free survival (PFS) between arms. II. To assess and compare locoregional failure and distant metastasis between arms . III. To assess acute and late toxicity (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0). IV. To assess patient-reported outcomes quality of life (PRO/QOL), as measured by the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) (primary PRO), between arms. V. To assess hearing loss, as measured by audiograms and the modified TUNE grading scale between arms. VI. To assess hearing loss, as measured by speech audiometry Consonant-Nucleus-Consonant word scores and tympanometry (subject to the modified TUNE grading scale testing results; otherwise, it will be an exploratory objective). VII. To assess hearing-related QOL as measured by the Hearing Handicap Inventory-Screening (HHIA-S) (secondary PRO), between arms. EXPLORATORY OBJECTIVE: I. To collect blood and tissue specimens for future translational science studies. For instance, to examine how germline and somatic genetic variants, such as TP53, CDKN2A, PIK3CA, PTEN, NFE2L2, and KEAP1, may influence cisplatin-related efficacy and toxicity, and to assess the effect of regular nonsteroidal anti-inflammatory drugs (NSAIDs) use and genomic activation of PIK3CA (mutation or amplification) or loss of PTEN, the negative regulator of PI3K, on disease-free survival or overall survival. OUTLINE: Patients are assigned to 1 of 2 groups. GROUP I (NON-OROPHARYNGEAL CANCER [OPC]/p16-NEGATIVE OPC): Patients are randomized to 1 of 2 arms. ARM I: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin intravenously (IV) once every 3 weeks (Q3W) (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV once a week (QW) during radiation therapy in the absence of disease progression or unacceptable toxicity. GROUP II (p16-POSITIVE OPC/CANCER OF UNKNOWN PRIMARY [CUP]): Patients are randomized to 1 of 2 arms. ARM III: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity. ARM IV: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1 month, every 3 months during year 1-2, every 6 months during year 3-5, then annually thereafter.